Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 08 04:00PM ET
2.05
Dollar change
-0.07
Percentage change
-3.30
%
IndexRUT P/E- EPS (ttm)-2.79 Insider Own22.62% Shs Outstand59.24M Perf Week-1.44%
Market Cap144.87M Forward P/E- EPS next Y-2.22 Insider Trans0.00% Shs Float54.69M Perf Month-6.39%
Income-171.30M PEG- EPS next Q-0.52 Inst Own71.85% Short Float15.73% Perf Quarter-15.98%
Sales0.00M P/S- EPS this Y34.70% Inst Trans-7.66% Short Ratio6.98 Perf Half Y-59.33%
Book/sh3.97 P/B0.52 EPS next Y-2.96% ROA-52.07% Short Interest8.60M Perf Year-93.23%
Cash/sh3.39 P/C0.61 EPS next 5Y- ROE-56.29% 52W Range1.79 - 30.20 Perf YTD-17.00%
Dividend Est.- P/FCF- EPS past 5Y-148.81% ROI-58.85% 52W High-93.21% Beta0.37
Dividend TTM- Quick Ratio14.19 Sales past 5Y0.00% Gross Margin- 52W Low14.53% ATR (14)0.14
Dividend Ex-Date- Current Ratio14.19 EPS Y/Y TTM0.34% Oper. Margin0.00% RSI (14)39.93 Volatility5.05% 6.38%
Employees80 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price12.17
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q50.21% Payout- Rel Volume0.54 Prev Close2.12
Sales Surprise- EPS Surprise22.25% Sales Q/Q- EarningsAug 08 AMC Avg Volume1.23M Price2.05
SMA20-8.56% SMA50-4.94% SMA200-42.63% Trades Volume668,330 Change-3.30%
Date Action Analyst Rating Change Price Target Change
Mar-12-24Upgrade Wells Fargo Equal Weight → Overweight $7 → $16
Mar-12-24Upgrade Oppenheimer Perform → Outperform $12
Nov-07-23Downgrade Wells Fargo Overweight → Equal Weight $77 → $8
Nov-07-23Downgrade Stifel Buy → Hold $6
Nov-07-23Downgrade Oppenheimer Outperform → Perform
Nov-07-23Downgrade Morgan Stanley Overweight → Equal-Weight $46 → $6
Nov-07-23Downgrade H.C. Wainwright Buy → Neutral
Jun-14-23Resumed Credit Suisse Outperform $63
Mar-21-23Initiated Wells Fargo Overweight $77
Dec-19-22Initiated Goldman Buy $50
Sep-23-24 01:54PM
08:00AM
Sep-06-24 08:00AM
Aug-30-24 08:00AM
07:04AM
08:00AM Loading…
Aug-28-24 08:00AM
Aug-08-24 04:01PM
Jul-30-24 05:13PM
Jul-29-24 08:00AM
08:00AM
Jun-05-24 04:01PM
May-16-24 04:05PM
11:23AM
08:00AM
May-13-24 09:02PM
10:37AM Loading…
10:37AM
May-09-24 08:59PM
04:01PM
May-02-24 04:05PM
Apr-30-24 12:00PM
Apr-17-24 08:45AM
05:45AM
Apr-15-24 01:15PM
Mar-27-24 06:20AM
Mar-20-24 05:45AM
Mar-18-24 06:02PM
Mar-11-24 07:29AM
07:00AM
Mar-07-24 08:52AM
08:00AM
08:00AM Loading…
Mar-06-24 08:00AM
Mar-04-24 08:00AM
Feb-27-24 04:01PM
Feb-22-24 07:00AM
Feb-21-24 04:09PM
Feb-06-24 04:05PM
Dec-23-23 11:01AM
Nov-21-23 04:05PM
Nov-10-23 08:00AM
Nov-09-23 04:01PM
09:35AM
Nov-07-23 04:20PM
08:47AM
07:00AM
Nov-06-23 04:01PM
Nov-04-23 12:16PM
Oct-11-23 11:37AM
Oct-10-23 04:18PM
12:55PM
07:44AM
Oct-09-23 04:01PM
Oct-07-23 05:00AM
Oct-04-23 11:01PM
Sep-29-23 12:43PM
Sep-08-23 05:07PM
Aug-30-23 04:05PM
Aug-15-23 07:23AM
Aug-10-23 04:01PM
Aug-03-23 04:05PM
Aug-02-23 04:06PM
Jul-12-23 07:22AM
Jul-03-23 02:09PM
Jun-14-23 07:00AM
Jun-07-23 07:00AM
May-31-23 08:00AM
May-12-23 08:57AM
May-11-23 04:01PM
May-04-23 04:05PM
Mar-27-23 07:12AM
Mar-24-23 11:13AM
08:00AM
Mar-23-23 04:01PM
Mar-15-23 04:05PM
Mar-13-23 09:02AM
Mar-11-23 01:21PM
Feb-28-23 08:00AM
Feb-27-23 08:50AM
Feb-13-23 09:55AM
Feb-10-23 08:50AM
Feb-03-23 12:00PM
Jan-26-23 09:55AM
08:00AM
Jan-25-23 08:50AM
Jan-12-23 08:00AM
Jan-05-23 08:00AM
Jan-04-23 09:55AM
Dec-27-22 07:11AM
Dec-22-22 07:26AM
Dec-01-22 04:05PM
Nov-22-22 08:00AM
Nov-11-22 06:35PM
Nov-03-22 04:01PM
Oct-27-22 04:05PM
09:00AM
Oct-24-22 09:55AM
Sep-19-22 09:31AM
08:00AM
Sep-16-22 07:16PM
Sep-14-22 02:01PM
Aug-29-22 04:05PM
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mohan RajuCEO AND PRESIDENTJun 10 '24Option Exercise0.2096,77819,3561,675,028Jun 11 04:47 PM
Krueger Christopher WCHIEF BUSINESS OFFICERApr 02 '24Sale5.401,6518,921284,999Apr 03 07:37 PM
Nuss JohnCHIEF SCIENTIFIC OFFICERApr 02 '24Sale5.401,6518,921264,998Apr 03 07:33 PM
Mohan RajuCEO AND PRESIDENTApr 02 '24Sale5.404,31223,2991,578,250Apr 03 07:32 PM
Auster MartinCHIEF FINANCIAL OFFICERApr 02 '24Sale5.401,4057,59224,303Apr 03 07:30 PM
Krueger Christopher WCHIEF BUSINESS OFFICERMar 28 '24Option Exercise0.004,5310286,650Mar 29 06:15 PM
Auster MartinCHIEF FINANCIAL OFFICERMar 28 '24Option Exercise0.004,531025,708Mar 29 06:12 PM
Mohan RajuCEO AND PRESIDENTMar 28 '24Option Exercise0.0011,84301,582,562Mar 29 06:09 PM
Nuss JohnCHIEF SCIENTIFIC OFFICERMar 28 '24Option Exercise0.004,5310266,649Mar 29 06:07 PM
Nuss JohnChief Scientific OfficerDec 20 '23Sale2.1217,62837,334262,118Dec 21 08:14 PM
Krueger Christopher WChief Business OfficerDec 20 '23Sale2.125,29311,210282,119Dec 21 08:12 PM
Mohan RajuCEO and PresidentDec 20 '23Sale2.1258,860124,6601,570,719Dec 21 08:10 PM
Mohan RajuCEO and PresidentDec 17 '23Option Exercise0.00116,66801,629,579Dec 19 05:30 PM
Nuss JohnChief Scientific OfficerDec 17 '23Option Exercise0.0034,9310279,746Dec 19 05:27 PM
Krueger Christopher WChief Business OfficerDec 17 '23Option Exercise0.0010,4790287,412Dec 19 05:25 PM
NSV Partners III LP10% OwnerOct 09 '23Sale30.0349,1521,475,8588,439,635Oct 11 04:21 PM
Subramaniam SomuDirectorOct 09 '23Sale30.0349,1521,475,8588,439,635Oct 11 04:18 PM